PFE vs PPBT

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...

Purple Biotech targets high-unmet-need oncology markets with a promising diversified pipeline, including the novel CAPTN-3 tri-specific antibody platform progressing towards IND (Q4 2026) and two Phase 2 assets (CM24, NT219) positioned for partnerships, indicating substantial TAM and significant 10x potential upon clinical success. A crucial positive development since the last analysis is the exte...